ストックスクリーナーアプリを入手
9.71
0.61%
-0.06
プレマーケット:
9.45
-0.26
-2.68%
Ocular Therapeutix Inc (OCUL) 最新ニュース
Equity-Based Pay at Ocular Therapeutix Raises Insider Trading Perception and Governance Risks - TipRanks
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c) - TipRanks
Ocular Therapeutix Q1 Earnings Call Highlights - Yahoo Finance
Ocular Therapeutix Q1 2026 Earnings Call Transcript - MarketBeat
OCUL: AXPAXLI's phase III success in wet AMD drives NDA plans and commercial readiness, backed by strong cash reserves - TradingView
Ocular Therapeutix's Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss By Investing.com - Investing.com Canada
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss - Investing.com
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips - ChartMill
OCULAR THERAPEUTIX ($OCUL) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Loss $0.40 a Share, vs. FactSet Est of $0.31 Loss - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings - TradingView
Ocular Therapeutix: Q1 Earnings Snapshot - marketscreener.com
Ocular Therapeutix 1Q 2026: Revenue $10.79M, Net income ($88.61M), EPS ($0.4) — 10-Q Summary - TradingView
[10-Q] OCULAR THERAPEUTIX, INC Quarterly Earnings Report - Stock Titan
Ocular Therapeutix reports Q1 2026: $10.8M revenue, $88.6M net loss, $666.7M cash - TradingView
OCUL: AXPAXLI's Phase 3 success in wet AMD drives NDA plans amid rising R&D costs and strong cash position - TradingView
Ocular Therapeutix (NASDAQ: OCUL) widens Q1 loss while advancing AXPAXLI Phase 3 trials - Stock Titan
MSN Money - MSN
Ocular Therapeutix Q1 2026 earnings preview - MSN
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance UK
Ocular Therapeutix earnings up next as AXPAXLI NDA looms By Investing.com - Investing.com South Africa
Ocular Therapeutix earnings up next as AXPAXLI NDA looms - Investing.com
OCULAR THERAPEUTIX, INC ($OCUL) CEO 2025 Pay Revealed - Quiver Quantitative
How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial - Yahoo Finance
Ocular Therapeutix (NASDAQ: OCUL) outlines 2026 proxy and 10M-share incentive plan increase - Stock Titan
[ARS] OCULAR THERAPEUTIX, INC SEC Filing - Stock Titan
Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD - marketscreener.com
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL) - Yahoo Finance
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds - MSN
Ocular Therapeutix (OCUL) Begins Patient Enrollment in Axpali Tr - GuruFocus
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data - Insider Monkey
Ocular Therapeutix enrolls first patient in wet AMD extension trial By Investing.com - Investing.com Australia
Ocular Therapeutix enrolls first patient in wet AMD extension trial - Investing.com
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD - Yahoo Finance
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences - Sahm
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 - The Manila Times
May 5 at 8 a.m. ET: Ocular Therapeutix to discuss Q1 results - Stock Titan
Ocular Therapeutix gains amid takeover speculation - MSN
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data - MarketBeat
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC - MarketBeat
Ocular lines up May talks on AMD trial data and investor webcasts - Stock Titan
Ocular Therapeutix prices $475M stock offering - MSN
Avoiding Lag: Real-Time Signals in (OCUL) Movement - Stock Traders Daily
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):